title: Conservative treatment of early glottic carcinomas with exclusive radiotherapy.
abstract: BACKGROUND
  Early glottic carcinomas can be treated with radiotherapy or surgery with similar local control rates but with better functional results with radiotherapy. The aim of this study was to analyze the results of our experience of exclusive radiotherapy.
  
  
  METHODS
  From 1975 to 2001, 155 patients with Tis, T1 and T2 glottic carcinomas were treated with exclusive radiotherapy. Prognostic factors of survival, local control and larynx-preservation rates were analyzed in uni and multivariate analyses.
  
  
  RESULTS
  Median prescribed dose was 65 Gy in 44 days. Overall survival was 75% for the whole group, 75% for Tis, 85% for T1a, 72% for T1b, 59% for T2. Specific survival was 88% for the whole group, 75% for Tis, 94% for T1a, 90% for T1b, 69% for T2. Disease-free survival was 68% for the whole group, 75% for Tis, 77% for T1a, 51% for T1b, 58% for T2. Laryngeal preservation rate was 85% (133/155). Twenty-nine (29/155, 18%) patients developed a local relapse within 31 months. Out of the 10/86 (12%) T1a-Tis relapses, 7/10 patients underwent total laryngectomy and 79/86 larynx were preserved (92%). Out of the 8/22 (36%) T1b relapses, 4/8 patients underwent total laryngectomy. Out of the 11/47 (23%) T2 relapses, 8/11 patients underwent total laryngectomy. Increased overall treatment time, tumor stage, sub-glottis extension were associated with poorer local control. Second malignancies remain a major problem in the outcome of this population.
  
  
  CONCLUSIONS
  Radiotherapy remains an efficient option in the treatment of early glottic carcinomas providing a high local control rate with excellent functional results in laryngectomy-free patients. This strategy should be discussed according to the tumor stage, feasibility of conservative surgery and patient's preferences.
authors.affiliation: Department of Radiation Oncology, Centre Georges-François Leclerc, 1, rue Pr-Marion, 21079 Dijon, France.
authors.forename: J
authors.initials: J
authors.lastname: Thariat
authors.forename: Y
authors.initials: Y
authors.lastname: Bruchon
authors.forename: F
authors.initials: F
authors.lastname: Bonnetain
authors.forename: I
authors.initials: I
authors.lastname: Barillot
authors.forename: G
authors.initials: G
authors.lastname: Truc
authors.forename: K
authors.initials: K
authors.lastname: Peignaux
authors.forename: J C
authors.initials: JC
authors.lastname: Horiot
authors.forename: P
authors.initials: P
authors.lastname: Maingon
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D019583:Dose Fractionation, Radiation; D005260:Female; D005931:Glottis / Q000473:pathology; D006801:Humans; D007822:Laryngeal Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D007825:Laryngectomy; D007828:Laryngoscopy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy; D016019:Survival Analysis; D013997:Time Factors; D014831:Voice
chemical_list: D003037:Cobalt Radioisotopes